Ovarian yolk sac tumour is a relatively uncommon ovarian neoplasm; however, it is one of the most common malignant ovarian neoplasms of childhood, adolescence and early adult life (Huntington et al., 1963) . Yolk sac tumours exhibit a wide range of histological subtypes that differ considerably from each other and, although all the different subtypes are frequently observed in the same tumour, one or two may predominate (Teilum, 1965 (Teilum, , 1968 (Teilum, , 1976 Duval, 1891; Jimerson & Woodruff, 1977) . The majority of ovarian yolk sac tumours show a distinctive subtype with differentiation towards yolk sac or vitelline structures (Teilum, 1959; Kurman & Norris, 1976; Huntingdon & Bullock, 1970) , and should be termed yolk sac tumour. During embryogenesis, the primary yolk sac differentiates during the second week of gestation, the secondary yolk sac in the third week and the primitive gut and liver tissues in the fourth to fifth weeks of gestation. In comparing the embryonic structures with the neoplastic subtypes, these various embryonic stages correspond to the endodermal sinus, polyvesicular vitelline, glandular and hepatoid subtypes respectively. Therefore, yolk sac tumours with glandular or hepatoid subtypes reflect more advanced stages of differentiation than those with pure endodermal sinus subtypes. Kurman and Norris (1976) dividied the components of endodermal sinus tumour into five main histological subtypes, but they were unable to determine any correlation of these with prognosis. YST of the ovary is a highly malignant neoplasm, metastasising early and invading the surrounding structures and organs. The tumour is very aggressive locally, and spread beyond the ovary is observed in a number of patients at the time of operation. Recurrences in the pelvis are very frequent, even when the tumour and the affected adnexa have been excised completely (Huntington et al., 1963; Kurman & Norris, 1976; Huntington, 1970; Neubeccker & Breen, 1962; Talerman et al., 1978) . In recent years there has been marked improvement in prognosis with adjuvant multiagent combination chemotherapy. Previously, a combination of vincristine, dactinomycin and cyclophosphamide Correspondence: H. Sasaki, Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8, Nishi-shinbashi, Minato-ku, Tokyo 105, Japan. This study was carried out with ethical committee approval of all institutes. Received 29 July 1993; and in revised form 22 September 1993.
(VAC) was the standard regimen for the treatment of germ cell tumours (Gershenson et al., 1985) . However, a combination of cisplatin, etoposide and bleomycin (BEP) (Smales & Peckman, 1987; Pinkerton et al., 1986; Gershenson et al., 1990; Williams et al., 1989) or cisplatin, vinblastine and bleomycin (PVB) (Bradof et al., 1982; Taylor et al., 1985; Einhorn & Donohue, 1977; Julian et al., 1980; Carlson et al., 1983; Davis et al., 1984) has been found to be even more effective and has produced remissions in patients with advanced-stage disease and in patients in whom other combinations of multiagent chemotherapy have failed (Bradof et al., 1982; Taylor et al., 1985; Einhorn & Donohue, 1977; Julian et al., 1980; Carlson et al., 1983; Davis et al., 1984; Smales & Peckman, 1987; Pinkerton et al., 1986; Williams et al., 1989; Gershenson et al., 1990) . Cisplatin-based combination chemotherapy has revolutionised the treatment of patients with yolk sac tumour.
We thought that differences in histological subtypes might have prognostic significance. Recently it was reported that the intestinal subtype (primitive endodermal) is histologically more differentiated, and this subtype is found more often in stage I patients (Kawai et al., 1991) . In the same study, the intestinal and microcystic subtypes were more common in survivors than in non-survivors, but the number of patients was considered to be too small for analysis (Kawai et al., 1991) . More extensive studies are needed to determine whether intestinal and hepatoid subtypes are biologically different from other types of YST.
In this report, clinicopathological evaluation was performed in 35 patients with pure YST of the ovary, particularly those with stage I disease, to determine if there is a correlation between prognosis and the various histological subtypes.
Patients and methods
The study group consisted of 35 patients (Table I) with pure yolk sac tumours of the ovary. The 35 patients were from 16 centres: the Departments of Obstetrics and Gynaecology of Nagasaki University (2), Kurume University (4), National Kyushu Cancer Centre (CTR) (3), Nagoya University (3), National CTR (5), Kitazato University (2), The Jikei University (1), Tohoku University (1), National Sendai Hospital (3) Niigata University (2) and Sapporo Medical University (9). All patients had primary surgery performed prior to chemotherapy or irradiation from 1963 to 1989. The 35 patients were all (Teilum, 1959 (Teilum, , 1976 ), Kurman's (Kurman & Norris, 1976 ) and Ulbright's methods (Ulbright et al., 1986) , which was composed of ES, PV, G and H subtypes. The ES subtype is consistent with Kurman's reticular subtype containing Schillar-Duval bodies (Figure 1 ) (Kurman & Norris, 1976) . The PV subtype corresponds to Kurman's polyvesicular vitelline subtype (Figure 2 ) (Kurman & Norris, 1976) . The G subtype is equal to Ulbright's enteric differentiation ( Figure 3 ) (Ulbright et al., 1986) . The H subtype is equal to Ulbright's hepatic differentiation (Figure 3 ) (Ulbright et al., 1986 
days).
Statistical analysis The survival rates were calculated using the Kaplan-Meier method (Kaplan & Meier, 1972) . Differences in survival among various groups were assessed with the log-rank test. In order to further analyse prognostic factors, we adopted the proportional hazard regression model of Cox (1972) plasm ( x 100). performance status, 0 = 1, = 2, 2 = 3, 3 = 4, 4 = 5; residual tumour size; nil or micro = 1, < 2 cm = 2, >2 cm to (5 cm = 3, >5 cm =4. In FIGO stage I cases alone, the variables in the Cox model were as follows: FIGO stage I subclasses, Ia = 1, lb = 1, Ic = 2; number of histological subtypes, one = 3, two = 2, three or four = 1; chemotherapy, cisplatin-based chemotherapies = 1, others = 2. All analyses were performed with standard packages from the Statistical Analysis System (SAS, Cary, NC, USA) (SAS Institute, 1983 , 1985 by S. Tsugane (National Cancer Research Institute, Tokyo, Japan).
Results

Clinicalfindings
The days and seven died between 254 and 1,248 days after primary therapy. The mean and standard deviation of the number of courses of VAC given to the two groups were 13.0 ± 6.98 in survivors and 15.3 ± 11.0 in non-survivors. There was no statistically significant difference in the number of courses of VAC (P>0.05, t-test). Thirteen of 35 patients (37.1%) were treated with cisplatin-based chemotherapy (PVB, 6; PAC, 3; PEP, 3; PAF, 1). Of the 13 patients, eight survived for 146-3,304 days and five died between 170 and 1,096 days after primary therapy. The number of courses of PVB given to the two groups was 3.6 ± 2.5 in survivors and 5.0 ± 1.2 in non-survivors. There was no statistically significant difference in the number of courses of PVB (P> 0.05, t-test). All of the three patients who received FAM or FAMT died 398-935 days after primary therapy. Other chemotherapeutic regimens were utilised in six patients (20.0%): carboquinone + 5-FU (1), CPM + MMC (1), MMC (1), ActD + carboquine (1), bleomycin (1) and methotrexate (1). Two patients received no adjuvant chemotherapy.
Prevalence of histological subtypes The prevalence of endodermal sinus subtype, polyvesicular vitelline subtype, glandular subtype and hepatoid subtype of YST is shown in Table I . The distribution of histological subtypes in all stages is also shown in Table I . The ES subtype was found in almost all (91.4%) YSTs. The other three subtypes, PV (Figure 2 ), G ( Figure 3 ) and H (Figure 4) , occurred much less frequently, with the PV subtype being least frequent. On the other hand in FIGO stage I cases, the frequency of ES subtype decreased, whereas that of PV, G and H subtypes increased.
In addition, the number of subtypes admixed in YSTs was examined (Table I) (SAS Institute, 1983 , 1985 . (Table  IV) . Therefore, the admixture of histological subtypes was an important prognostic factor in FIGO stage I patients. (Teilum, 1959 (1959, 1965, 1968, 1976) . Subsequently, Kurman and Norris (1976) In the present study, the definition of the hepatoid subtype, which was first described by Prat et al. (1982) , was based on Ulbright's criteria (Ulbright et al., 1986) , i.e. hepatoid areas characterised by nest and cords of polygonal, acidophilic cells with prominent nucleoli and intense cytoplasmic staining for alpha-fetoprotein. Ulbright et al. (1986) noted that this subtype occurred in 22% of YSTs. We found a slightly higher prevalence of 40%.
Enteric differentiation occurred as well-defined glands with a sharp, striated border and relatively bland nuclear features (Ulbright et al., 1986) . Salazar et al. (1974) 11.45a (11,11,25, 31,36 108, 1,650, 13,400 14,800, 178,500 0 7.6 + 4.04k, ' 3, 6, 7, 8, 14 3 2 Three or four subtypes 7 24. 57+8.75c,d (14,14,22,23, 30,34,35) Ulbright's enteric differentiation (Ulbright et al., 1986) . Recently, the International Society of Gynecological Pathologists proposed a new classification of YST of the ovary (International Society of Gynecological Pathologists, 1990 (Einhorn & Donohue, 1977; Julian et al., 1980; Carlson et al., 1983; Davis et al., 1984) . However, our data showed that chemotherapy regimen was not a significant predictor in FIGO stage I patients. In FIGO stage I, VAC produced a high proportion of cures, but in patients with metastatic disease the sustained remission rates of cisplatin-based chemotherapies are better than that of VAC (Pinkerton et al., 1986; Williams et al., 1989; Gershenson et al., 1990) . Therefore, our results of multivariate analysis in FIGO stage I patients are not consistent with other reports concerning chemotherapy for ovarian YST. In addition, there were no significant differences between groups with an admixture of histological subtypes and that with one subtype with respect to the number of patients treated with cisplatin-based chemotherapies, although patients with three or four subtypes had a better outcome than patients in other groups.
Next, age was considered as a possible prognostic factor. Some investigators have reported that there are no significant differences in prognosis between those younger and older than 20 years of age (Kurman & Norris, 1976; Kawai et al., 1991) . In the present study, multivariate analysis showed the same result as other reports. In addition, patients less than 10 years of age are known to have a worse prognosis, and in our series no FIGO stage I patient was less than 10 years old.
There were no statistically significant differences in the factors mentioned above among the three groups with different numbers of histological subtypes. However, there was a significant difference in alpha-fetoprotein between the stage I patients with two subtypes and those with three or four subtypes. However, both univariate and multivariate analysis showed no prognostic significance in relation to alpha-fetoprotein in this study. There are previous reports indicating that preoperative alpha-fetoprotein levels do not correlate with prognosis (Kawai et al., 1991) . Therefore, it can be considered that histological subtype is superior to other factors as a predictor in FIGO stage I YST of the ovary.
When we focused on the number of histopathological slides, there were variations in the numbers of slides examined for each histological subtype. The mean number of slides studied for tumours containing three or four subtypes was greater than that for tumours with one or two subtypes. There was a wide variation in the number of slides reviewed per patient. However, when statistical analysis was performed, there were no significant differences between tumours with one or two subtypes and those with three or four subtypes. However, when the group with three or four subtypes was separated for comparison with other groups, comparison of the group with one subtype and that with three subtypes showed a significant difference. Even though there were no significant differences in comparing the numbers of slides examined in the groups with three or four subtypes with other groups, it was thought that the number of subtypes might increase in some cases after histopathological examination of a large number of slides, especially in the tumours containing only one subtype.
Generally, it is agreed that well-differentiated germ cell tumours have better prognosis than undifferentiated ones. In comparing embryonic structures with neoplastic subtypes, YSTs containing three or four distinct subtypes may be better differentiated tumours that pure endodermal sinus tumours. If the concept were reasonable, it would be that patients with tumours containing three or four subtypes have a better prognosis than those with tumours containing one or two subtypes. Therefore, it could be clinically important to investigate the prognostic significance of histological subtype in stage I YST. The present study was a retrospective investigation, and may have a bias in the numbers of histopathological slides examined. We consider that a prospective study with identical pathological examinations is necessary to confirm the correlation between histological subtype and the clinical outcome in stage I pure yolk sac tumour of the ovary.
Although stage I pure yolk sac tumour generally has a good prognosis, the present study suggests that the different subtypes may have prognostic significance. In particular, endodermal sinus subtype alone is associated with a poor prognosis, which may have therapeutic implications.
